Double dose of deals as Celgene buys Avila, Amgen nabs Micromet

Celgene ($CELG) snapped up Avila Therapeutics and its early-stage Btk inhibitor in a "grand slam" buyout that could hit $925 million with milestone payments. And not to be left out of the day's M&A fervor, Amgen ($AMGN) picked up Micromet ($MITI) for $1.2 billion, citing its "better way to kill tumor cells" as part of the attraction. Article | Report

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.